KR102845328B1 - 인지 장애의 치료시 사용하기 위한 3β-(벤질옥시)-17α-메틸-프레근-5-엔-20-온 - Google Patents

인지 장애의 치료시 사용하기 위한 3β-(벤질옥시)-17α-메틸-프레근-5-엔-20-온

Info

Publication number
KR102845328B1
KR102845328B1 KR1020217019491A KR20217019491A KR102845328B1 KR 102845328 B1 KR102845328 B1 KR 102845328B1 KR 1020217019491 A KR1020217019491 A KR 1020217019491A KR 20217019491 A KR20217019491 A KR 20217019491A KR 102845328 B1 KR102845328 B1 KR 102845328B1
Authority
KR
South Korea
Prior art keywords
3bn17mep
cognitive
mice
cognitive impairment
rimonabant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217019491A
Other languages
English (en)
Korean (ko)
Other versions
KR20210124962A (ko
Inventor
삐에-빈센조 삐아쨔
쌍디 파브르
스테파니 몽레중
마틸드 멧나
모니끄 발레
쟝-미셸 헤베스트
다니엘라 꼬따
지오바니 마시까노
알린 마리게또
안드레스 오자이타
라파엘 말도나도
Original Assignee
앨리스 파마
유니베르시떼 드 보르도
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앨리스 파마, 유니베르시떼 드 보르도, 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 filed Critical 앨리스 파마
Publication of KR20210124962A publication Critical patent/KR20210124962A/ko
Application granted granted Critical
Publication of KR102845328B1 publication Critical patent/KR102845328B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217019491A 2018-12-18 2019-12-18 인지 장애의 치료시 사용하기 위한 3β-(벤질옥시)-17α-메틸-프레근-5-엔-20-온 Active KR102845328B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306716.4 2018-12-18
EP18306716.4A EP3669876A1 (en) 2018-12-18 2018-12-18 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
PCT/EP2019/085927 WO2020127468A1 (en) 2018-12-18 2019-12-18 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS

Publications (2)

Publication Number Publication Date
KR20210124962A KR20210124962A (ko) 2021-10-15
KR102845328B1 true KR102845328B1 (ko) 2025-08-12

Family

ID=65278139

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019491A Active KR102845328B1 (ko) 2018-12-18 2019-12-18 인지 장애의 치료시 사용하기 위한 3β-(벤질옥시)-17α-메틸-프레근-5-엔-20-온

Country Status (26)

Country Link
US (1) US12583884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3669876A1 (cg-RX-API-DMAC7.html)
JP (1) JP7515480B2 (cg-RX-API-DMAC7.html)
KR (1) KR102845328B1 (cg-RX-API-DMAC7.html)
CN (1) CN113260366B (cg-RX-API-DMAC7.html)
AU (1) AU2019409912B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118210C (cg-RX-API-DMAC7.html)
CL (1) CL2021001458A1 (cg-RX-API-DMAC7.html)
DK (1) DK3897655T3 (cg-RX-API-DMAC7.html)
ES (1) ES2987823T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897655T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241376T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068626T2 (cg-RX-API-DMAC7.html)
IL (1) IL284032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897655T (cg-RX-API-DMAC7.html)
MA (1) MA54518B1 (cg-RX-API-DMAC7.html)
MD (1) MD3897655T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006904A (cg-RX-API-DMAC7.html)
PL (1) PL3897655T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897655T (cg-RX-API-DMAC7.html)
RS (1) RS66013B1 (cg-RX-API-DMAC7.html)
SI (1) SI3897655T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400425T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020127468A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103284B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
WO2024085245A1 (ja) 2022-10-21 2024-04-25 国立大学法人高知大学 術後せん妄の抑制薬

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515361A (ja) * 2011-05-20 2014-06-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Cb1受容体のアンタゴニスト
US20160067235A1 (en) * 2013-03-19 2016-03-10 Universitat Pompeu Fabra Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234125A1 (en) 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
CN101790521A (zh) 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
RU2667065C2 (ru) * 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
IL276697B2 (en) 2018-02-20 2024-08-01 Aelis Farma 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515361A (ja) * 2011-05-20 2014-06-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Cb1受容体のアンタゴニスト
US20160067235A1 (en) * 2013-03-19 2016-03-10 Universitat Pompeu Fabra Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities

Also Published As

Publication number Publication date
HUE068626T2 (hu) 2025-01-28
DK3897655T3 (da) 2024-09-23
IL284032A (en) 2021-08-31
CN113260366B (zh) 2024-03-08
HRP20241376T1 (hr) 2024-12-20
MA54518B1 (fr) 2024-11-29
AU2019409912A1 (en) 2021-05-27
JP7515480B2 (ja) 2024-07-12
PL3897655T3 (pl) 2025-01-13
IL284032B1 (en) 2025-01-01
EP3897655B1 (en) 2024-07-17
MD3897655T2 (ro) 2024-12-31
PT3897655T (pt) 2024-10-14
AU2019409912A8 (en) 2021-06-17
KR20210124962A (ko) 2021-10-15
US20220017562A1 (en) 2022-01-20
SI3897655T1 (sl) 2025-04-30
RS66013B1 (sr) 2024-10-31
BR112021011654A2 (pt) 2021-09-08
WO2020127468A1 (en) 2020-06-25
CL2021001458A1 (es) 2022-01-21
EP3897655A1 (en) 2021-10-27
CA3118210A1 (en) 2020-06-25
MA54518A (fr) 2022-02-16
US12583884B2 (en) 2026-03-24
CA3118210C (en) 2024-05-21
SMT202400425T1 (it) 2024-11-15
CN113260366A (zh) 2021-08-13
JP2022515373A (ja) 2022-02-18
ES2987823T3 (es) 2024-11-18
FI3897655T3 (fi) 2024-09-17
ZA202103284B (en) 2024-09-25
LT3897655T (lt) 2024-10-10
AU2019409912B2 (en) 2025-02-20
MX2021006904A (es) 2021-09-30
EP3669876A1 (en) 2020-06-24
IL284032B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
US20220202798A1 (en) Use of pridopidine for the treatment of fragile x syndrome
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
NO327233B1 (no) Anvendelse av en glukokortikoidreseptorantagonist for fremstilling av et medikament til forbedring av psykose hos en pasient.
JP2009102343A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
WO2012054718A2 (en) Treating long qt syndrome
JP2020528938A (ja) ガラクトース血症を処置するための組成物および方法
CA2871233A1 (en) Use of lurasidone for treating mental and behavioural disorders
CN113260366B (zh) 3β- (苄氧基) -17α-甲基-孕甾-5-烯-20-酮用于治疗认知障碍
JP2003527342A (ja) 軽度認知障害を処置する方法
US20190015395A1 (en) Tacrolimus for treating tdp-43 proteinopathy
JP7254100B2 (ja) カンナビノイド関連障害の処置における使用のための3β-(4-メトキシベンジルオキシ)プレグン-5-エン-20-オン
CA3028629A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
RU2796005C2 (ru) 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ
WO2008008841A2 (en) Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders
HK40060558A (en) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
HK40060558B (en) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
RU2788004C2 (ru) 3-β(4-МЕТОКСИБЕНЗИЛОКСИ)ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ НАРУШЕНИЙ, СВЯЗАННЫХ С УПОТРЕБЛЕНИЕМ КАННАБИНОИДОВ
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
WO2024158972A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)